AstraZeneca set to licence 5 programmes from Transgène SA
With a licence option agreement AstraZeneca has won another possibility to complement its cancer immuno-oncology pipeline. The British drug major...
BioNtech aquires antibody assets from MabVax Therapeutics
Besides an undisclosed number of preclinical antibody candidates BioNTech has acquired MabVax Therapeutics’ Phase I candidate, MVT-5873, an antibody...
Hedging success
Setting the tone: successful entrepreneur Jean-Paul Clozel (Idorsia, formerly Actelion) warned of taking upcoming threats like populism too lightly....
Erytech Pharma SA bags US$57m from SQZ Biotechnologies
Under the agreement, Erytech will licence the rights to use its ERYCAPS platform to SQZ, which will combine it with its Cell Squeeze platform to...
Sanofi ends option phase of rare disease partnership with Alnylam
The companies announced that Sanofi will keep global commercialisation rights for fitusiran, an RNAi therapeutic under development for hemophilia A...
Genetically modified fungus stops malaria mosquitoes
In field trials in Burkina Faso, US researchers infected the mosquitoes with spores of the poisonous fungus Metarhizium pingshaense. Within six...
MS linked to epigenetic changes in immune cells
Previous analyses suggest that the activation of autoreactive T cells marks the onset of MS. Now, two research groups headed by Reinhard Hohlfeld...